Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Adverse events reported during the study

From: Therapeutic cancer vaccine: phase I clinical tolerance study of Hu-rhEGF-rP64k/Mont in patients with newly diagnosed advanced non-small cell lung cancer

Adverse events Group A - 0.6 mg Group B - 1.2 mg Group C - 1.8 mg Group D - 2.4 mg
n = 3 n = 3 n = 3 n = 3
AEs Patients AEs Patients AEs Patients AEs Patients
White blood cell decreased 1 1 1 1 1 1 2 1
ALT increased 1 1 0 0 1 1 0 0
Neutrophil count decreased 0 0 0 0 0 0 1 1
AST increased 0 0 0 0 1 1 0 0
Hemoglobin increased 1 1 0 0 0 0 0 0
Headache 0 0 0 0 3 3 0 0
Dizziness 4 2 4 3 5 3 0 0
Temporary amaurosis 0 0 1 1 0 0 0 0
Cough 0 0 0 0 1 1 0 0
Upper respiratory infection 1 1 0 0 0 0 0 0
Hyperhidrosis 0 0 0 0 1 1 0 0
Fever 0 0 1 1 1 1 0 0
Tremors 0 0 2 1 2 1 0 0
Face flushing 3 1 0 0 0 0 0 0
Injection site erythema 0 0 0 0 2 1 0 0
Injection site itching 0 0 0 0 1 1 0 0
injection site pain 3 1 2 2 0 0 0 0
Nausea 0 0 0 0 1 1 0 0
Total 14 11 20 3